臨床研究等提出・公開システム

An Observational Study on the Therapeutic Effects of Semaglutide for Obesity : Relationship to Patients' Eating Behavior Patterns

Treatment Response and Eating Behavior Patterns in Patients Using Semaglutide

Kato Takehiro

Gifu University Graduate School of Medicine

1-1, Yanagido, Gifu

sei6105@gmail.com

Banno Seiya

Gifu University Graduate School of Medicine

1-1 Yanagido, Gifu

+81-582306377

sei6105@gmail.com

Recruiting

May. 24, 2024

Observational

non-randomized controlled trial

open(masking not used)

uncontrolled control

factorial assignment

treatment purpose

Among obese patients newly started on semaglutide, those who understood the purpose of the study and gave their consent

1) Patients who have difficulty following the instructions of the principal investigator or sub-investigator
2) Other patients who are deemed inappropriate for this study by the principal investigator or sub-investigator.

obesity

obesity

obesity

Difference in BMI changes based on dietary preferences between the focus period and the reference period
(The 24 weeks prior to drug administration are the reference (control) period, and the 24 weeks from the start of drug administration are the focus (exposure) period.)

Based on dietary preferences
Differences in the changes in body weight, BMI, blood pressure, grip strength, respiratory quotient, body composition, bone density, blood biochemistry test results, and urine test (urine protein quantification) between the focus period and the reference period (The 24 weeks prior to drug administration are the reference (control) period, and the 24 weeks from the start of drug administration are the focus (exposure) period.)
Changes in body weight and BMI from baseline to 0, 24, and 52 weeks after administration
Changes in body weight, BMI, blood pressure, grip strength, respiratory quotient, body composition, bone density, dietary content (total energy intake, various nutrients, intake of each food item), blood biochemistry test results, and urine test (urine protein quantification) from baseline to 12, 24, and 52 weeks after administration
Changes in dietary preferences at 12, 24, and 52 weeks after drug administration
Based on dietary content
Differences in the changes in body weight, BMI, blood pressure, grip strength, respiratory quotient, body composition, bone density, blood biochemistry test results, and urine test (urine protein quantification) between the focus period and the reference period (The 24 weeks prior to drug administration are the reference (control) period, and the 24 weeks from the start of drug administration are the focus (exposure) period.)
Changes in body weight, BMI, blood pressure, grip strength, respiratory quotient, body composition, bone density, dietary content (total energy intake, various nutrients, intake of each food item), and blood biochemistry test results from baseline to 12, 24, and 52 weeks after administration
Medication adherence rate and medication details during the drug administration period

+81-58-230-6059

April. 17, 2024

No

none